COH:ASXCochlear Limited Analysis

Cochlear Limited is trading at AUD 174.42, well below its 20‑day (190.94), 50‑day (233.40) and 200‑day (275.01) SMAs, signalling a strong bearish price trend. RSI sits at 18.9, indicating the stock is deeply oversold, while the MACD histogram has turned positive and the signal line is deemed bullish, suggesting a possible short‑term rebound toward the near‑term support of AUD 169.03. Volume is increasing and volatility remains elevated at 63% over the past 30 days, adding both upside potential and downside risk.
Fundamentally, the company carries a trailing PE of 33.1 versus an industry average of 26.2 and a price‑to‑book of 5.9, implying the market is pricing in substantial growth expectations that are not yet reflected in earnings – forward PE improves to 24.9 but still signals overvaluation. The DCF‑derived fair value of roughly AUD 20.8 is dramatically lower than current levels, while the dividend yield of 2.47% is supported by an 81% payout ratio and solid cash flow, though free cash flow is modest. Revenue is flat year‑over‑year and profit margins have slipped, and regulatory scrutiny in the medical‑device space remains a key headwind. Overall, the stock appears oversold on a technical basis but remains fundamentally overvalued, with the dividend appearing sustainable in the near term.